No abstract

No abstract

Tideglusib®, a GSK-3 inhibitor, was initially tested for the treatment of Alzheimer’s disease. However, a recent report has suggested its potential off-label use for the treatment of dental cavities. Even if this effect is not yet confirmed, this off-label use can have significant public/dental health consequences, mainly because of the large number of patients with cavities. The purpose of this mini-review is to perform an ethical analysis of the use of Tideglusib in dentistry. The ethical analysis identified three main areas in which ethical breaches could be significant: 1) respect for the autonomy of the patient, 2) issues raised by horizontal shifts in the translational research process, and 3) the conflict between dental beneficence and general non-maleficence. In conclusion, the use of Tideglusib in dentistry should respect the same strict ethical and regulatory criteria from clinical medicine. A translation of the potential risks should be done only after large-scale, phase-III/IV clinical trials, explicitly designed to test the usefulness of this drug in dental medicine.

In the present environment of staggering technical innovations and increasing expectations of quality healthcare it is evident that we need to fine tune our diagnostic abilities in order to fulfil patients� demands for more efficient therapies and augmented quality of life. We are looking for current trends in clinical gynecology that make use of Liquid chromatography tandem mass spectroscopy, technology not yet employed in Romanian laboratories for the clinical practice but that is rapidly becoming the worldwide method of choice for accurate characterization of the hormonal milieu essential for the requirements of women healthcare.

The antigens of the HLA system represent a distinctive marker in identifying racial and population groups by means of an anthropological and relational characterization. Building a database is beneficial to forensic identification, to implement transplant programs and to determine a predisposition to certain illnesses. We performed the HLA class I serotyping on the antigens on HLA A and HLA B loci for 1250 unrelated individuals from the Romanian population; based on this we calculated the allelic frequency. The most frequent antigen on the HLA A locus was HLA A2, and on the HLA B locus was HLA B35. We subsequently compared the results we obtained for the Romanian population with similar data from several Balkan populations.